471 patents
Page 11 of 24
Utility
Human Cytomegalovirus GB Polypeptide
24 Mar 22
The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least two introduced amino acid mutations relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB).
Yuhang Liu, Ye Che, Xiaoyuan Sherry Chi, Philip Ralph Dormitzer, Jennifer Anne Nicki, Xiaojie Yao
Filed: 17 Jun 21
Utility
Novel 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) Carbaldehyde Derivatives
24 Mar 22
Hui LI, Seiji NUKUI, Stephanie Anne SCALES, Min TENG, Chunfeng YIN
Filed: 1 Dec 21
Utility
Method of Treating Signs and Symptoms of Osteoarthritis
24 Mar 22
The present invention relates to the treatment of signs and symptoms of osteoarthritis with an anti-nerve growth factor (NGF) antibody.
Christine Ruth WEST, Mark Thomas BROWN
Filed: 27 Jan 20
Utility
Substituted PYRAZOLO[1,5-A]PYRIDINE Compounds As Inhibitors of FGFR Tyrosine Kinases
17 Mar 22
James F. Blake, David A. MORENO, Li REN, Tony P. TANG, Shane M. WALLS
Filed: 13 Dec 19
Utility
Pharmaceutical Compositions and Methods Comprising A Combination of a Benzoxazole Transthyretin Stabilizer and an Additional Therapeutic Agent
10 Mar 22
The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a benzoxazole derivative transthyretin stabilizer or a pharmaceutically acceptable salt or prodrug thereof and an additional therapeutic agent for the treatment of transthyretin amyloidosis.
Christine Ellen Bulawa, James Allan Fleming
Filed: 17 Dec 19
Utility
Cells with reduced inhibitor production and methods of use thereof
10 Mar 22
The invention relates to a method of cell culture where the cells are modified to reduce the level of synthesis of growth and/or productivity inhibitors by the cell.
Emily Ann DEUTSCHMAN, Jeffrey Joseph MITCHELL, Bhanu Chandra MULUKUTLA, John Joseph SCARCELLI
Filed: 3 Dec 19
Utility
Nitrile-Containing Antiviral Compounds
3 Mar 22
Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Liuqing Wei, Qingyi Yang, Xiaojing Yang
Filed: 5 Aug 21
Utility
Synthesis of PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES
24 Feb 22
Adam Ross Brown, Jean-Nicolas Desrosiers, Shengquan Duan, Joel Michael Hawkins, Cheryl Myers Hayward, Mark Thomas Maloney, Sebastien Monfette, Hahdi Hakimioun Perfect, Daniel William Widlicka
Filed: 23 Sep 19
Utility
Method for Predicting Response to Breast Cancer Therapeutic Agents and Method of Treatment of Breast Cancer
24 Feb 22
Methods for treating triple negative breast cancer with an androgen receptor inhibitor are provided, as well as methods for screening for the likelihood of the effectiveness of such treatment.
Amy Christian PETERSON, Hirdesh UPPAL
Filed: 10 Nov 21
Utility
Combination of a PD-1 Antagonist, an Atr Inhibitor and a Platinating Agent for the Treatment of Cancer
17 Feb 22
The present invention relates to combination therapies useful for the treatment of cancer.
Marat Alimzhanov, Patricia Soulard, Frank Zenke, Heike Dahmen, Astrid Zimmermann, Andreas Schroeder, Keyvan Tadjalli Mehr, Martin Falk
Filed: 26 Sep 19
Utility
Ssi Cells with Predictable and Stable Transgene Expression and Methods of Formation
17 Feb 22
Mammalian cells are described that includes a recombination target site integrated within high integrating locus.
PETER M. O'CALLAGHAN, STEPHEN BEVAN, ROBERT YOUNG, PETER FRASER, LIN ZHANG
Filed: 1 Oct 19
Utility
Substituted Quinoxaline Compounds As Inhibitors of FGFR Tyrosine Kinases
10 Feb 22
James F. Blake, Li REN, David A. MORENO, Shane M. WALLS
Filed: 16 Dec 19
Utility
Recombinant Vaccinia Virus
3 Feb 22
The present disclosure provides human IL-2 variants, recombinant oncolytic viruses comprising the IL-2 variant, compositions comprising the IL-2 variant or recombinant oncolytic virus, and use of the IL-2 variants, recombinant oncolytic virus, or compositions for treating cancer in an individual.
Joseph John Binder, Michael Dale Eisenbraun, Clare Lees, Jeremy Shawn Myers, James Travis Patterson
Filed: 9 Jul 21
Utility
Combinations For Treatment Of NASH/NAFLD And Related Diseases
27 Jan 22
The combination of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or pharmaceutically acceptable salt thereof, and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or pharmaceutically acceptable salt thereof, for treatment of diseases, including non-alcoholic steatohepatitis (NASH), in mammals are described herein.
William Paul Esler, Trenton Thomas Ross
Filed: 11 Oct 21
Utility
Crystalline Forms of 1-((2R,4R)-2-(1H-BENZO[D]IMIDAZOL-2-YL)-1-METHYLPIPERIDIN-4-YL)-3-(4-CYANOPHENYL)UREA Maleate
27 Jan 22
This invention relates to a crystalline form of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, and to pharmaceutical compositions thereof, to intermediates and methods for the production and isolation of such crystalline forms and compositions, and to methods of using such crystalline forms and compositions in the treatment of abnormal cell growth in mammals, especially humans.
Eric Christian Hansen, Christopher Scott Seadeek
Filed: 6 Oct 21
Utility
Pneumococcal Dosing Regimen
27 Jan 22
Methods of immunizing older adult subjects against Streptococcus pneumoniae infection are provided.
George Rainer Siber, Peter R. Paradiso, Jill Hackell, Stephen Paul Lockhart, William P. Hausdorff
Filed: 5 Oct 21
Utility
Crystalline Forms of 1-((2R,4R)-2-(1H-BENZO[D]IMIDAZOL-2-YL)-1-METHYLPIPERIDIN-4-YL)-3-(4-CYANOPHENYL)UREA Maleate
27 Jan 22
This invention relates to a crystalline form of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, and to pharmaceutical compositions thereof, to intermediates and methods for the production and isolation of such crystalline forms and compositions, and to methods of using such crystalline forms and compositions in the treatment of abnormal cell growth in mammals, especially humans.
Eric Christian Hansen, Christopher Scott Seadeek, Anil Mahadeo Rane
Filed: 6 Oct 21
Utility
Btla Fusion Protein Agonists and Uses Thereof
27 Jan 22
The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response.
Carl F. WARE, John SEDY, Tigran AIVAZIAN, Brian MILLER, Natasha K. CRELLIN
Filed: 1 Mar 21
Utility
Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
20 Jan 22
The present invention relates to new glycoconjugates comprising Streptococcus pneumoniae capsular saccharide antigens and uses thereof.
Avvari Krishna Prasad, Jianxin Gu, Jin-Hwan Kim, Suddham Singh
Filed: 9 Dec 19
Utility
Compounds and Methods for the Treatment of COVID-19
20 Jan 22
Robert Steven Kania, Padmavani Bezawada, Emma Louise Hawking, Rohit Jaini, Samir Kulkarni, Matthew Nathan O'Brien Laramy, Jonathan Richard Lillis, Suman Luthra, Dafydd Rhys Owen, Klimentina Dimitrova Pencheva, Martin Youngjin Pettersson, Anil Mahadeo Rane, Matthew Forrest Sammons, Bradley Paul Sullivan, Andrew John Thiel, Martyn David Ticehurst, Jamison Bryce Tuttle, Robert Louis Hoffman
Filed: 1 Jul 21